Breaking Finance News

Galapagos NV (AMS:GLPG) has been upgraded from Sell to Neutral in a statement by Janney Capital earlier today.

Janney Capital has upgraded Galapagos NV (AMS:GLPG) from Sell to Neutral in a statement released on 7/07/2017.

Having a price of $75.63, Galapagos NV (AMS:GLPG) traded 3.29% higher on the day. With the last close up 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. GLPG has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. Trade Volume was up over the average, with 353,470 shares of GLPG changing hands over the typical 0

Recent Performance Chart

Galapagos NV (AMS:GLPG)

Galapagos NV has with a one year low of $52.50 and a one year high of $94.88 and has a market capitalization of $0.

A total of 1 analyst has released a report on Galapagos NV. zero analysts rating the company a strong buy, two analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $92.78.

General Company Details For Galapagos NV (AMS:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.